IDH2 and central nervous system cancer: Noteworthy, eight manuscripts addressed downregulation of immune checkpoint expression on tumor cells of IDH‐mutant glioma, with PDL‐1 downregulation emphasized in five of them, providing a direct mechanism for ICB resistance, in addition to the immunosuppressive TME.